-
11.
公开(公告)号:ES2296761T3
公开(公告)日:2008-05-01
申请号:ES01945242
申请日:2001-06-01
Applicant: HOFFMANN LA ROCHE
Inventor: GALLEY GUIDO , GODEL THIERRY , GOERGLER ANNICK , HOFFMANN TORSTEN , KOLCZEWSKI SABINE , ROEVER STEPHAN
IPC: C07D471/10 , A61K31/437 , A61K31/445 , A61P1/04 , A61P9/00 , A61P11/00 , A61P11/06 , A61P25/06 , A61P25/28 , A61P25/36 , A61P27/02 , A61P27/16 , A61P29/00 , A61P37/08 , A61P43/00
Abstract: Compuesto de la fórmula general en donde R1 es hidrógeno, alquilo C1-C7, alquenilo C1-C7, fenilo o los siguientes grupos -(CH2)m-heterociclilo no aromá-tico, elegido del grupo constituido por pirrolidinilo, 5-oxo-pirrolidinilo, 2-oxa-oxazolidinilo, piperidinilo, piperacinilo, orfolinilo, imidazolidinilo y pirazo-lidinilo, que está opcionalmente sustituido por alquilo inferior, o es -(CH2)m-heteroarilo, elegido del grupo constituido por piridinilo, 1, 3, 5-triacinilo, pirimidinilo, quinoxa-linilo, piracinilo, isoxazolilo, benzoimidazolilo, 1, 2, 4-oxadiazolilo, triazolilo, tetrazolilo, tiazolilo, tienilo, furilo, piranilo, pirrolilo, imidazolilo, pirazolilo, isotiazolilo, piperacinilo y piperidilo, que está opcionalmente sustituido por uno o dos sustituyentes elegidos del grupo constituido por alquilo C1-C7, alcoxi C1-C7, halógeno, CF3, bencilo o ciano, o es -(CH2)m-C(O)-NRR'', -(CH2)m-C(O)-alquilo C1-C7, -(CH2)m-C(O)-O-alquilo C1-C7, -(CH2)m-O-alquilo C1-C7, -(CH2)m-CH[C(O)-O-alquilo C1-C7]2, -(CH2) m-CH(OH)-CH2-O-fenilo, -(CH2)m-CH(CF3)OH, -(CH2)m-OH, -(CH2)m-CN, -(CH2)m-NRR'', -(CH2)m-cicloalquilo o -(CH2)m-CHF2; R2 es hidrógeno, alquilo C1-C7, halógeno o alcoxi C1-C7; R3 es alquilo C1-C7, alcoxi C1-C7, halógeno o CF3; R, R'' son iguales o diferentes y son hidrógeno o alquilo C1-C7; X es >N-, >C= o >CH-; X1/X2 son independientemente entre sí hidrógeno, hidroxi o alcoxi C1-C7 o juntos pueden ser un grupo oxo; Y1/Y2 son independientemente uno de otro hidrógeno, alquilo inferior, -(CH2)m-fenilo o juntos pueden ser un grupo oxo; Z es un enlace, -CH2 o -C(O)-; m es 0, 1, 2, 3 ó 4; n es 2 ó 3; n'' 0, 1 ó 2; y a sus sales de adición de ácido farmacéuticamente aceptables.
-
公开(公告)号:NO324841B1
公开(公告)日:2007-12-17
申请号:NO20030632
申请日:2003-02-07
Applicant: HOFFMANN LA ROCHE
Inventor: STADLER HEINZ , GODEL THIERRY , SCHNIDER PATRICK , HOFFMANN TORSTEN
IPC: C07D213/74 , A61K31/44 , A61K31/4427 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/455 , A61K31/496 , A61K31/5377 , A61P1/04 , A61P11/00 , A61P17/02 , A61P25/00 , A61P25/06 , A61P25/28 , A61P25/36 , A61P27/02 , A61P27/16 , A61P29/00 , A61P29/02 , A61P37/00 , A61P37/08 , A61P43/00 , C07D213/75 , C07D213/79 , C07D213/82 , C07D401/04 , C07D401/06 , C07D401/12 , C07D409/04 , C07D413/04 , C07D417/04 , C07D521/00
Abstract: Substituted 4-phenyl-pyridine compounds with activity as antagonists of Neurokinin 1 receptors, methods of making these compounds and preparing.
-
公开(公告)号:DE60126614T2
公开(公告)日:2007-11-22
申请号:DE60126614
申请日:2001-05-18
Applicant: HOFFMANN LA ROCHE
Inventor: GALLEY GUIDO , GOERGLER ANNICK , GODEL THIERRY , HECK REINHARD
IPC: C07D243/08 , A61K31/551 , A61K31/5517 , A61P1/04 , A61P1/08 , A61P9/00 , A61P11/06 , A61P13/10 , A61P17/02 , A61P19/02 , A61P25/00 , A61P25/06 , A61P27/02 , A61P29/00 , A61P37/08 , C07D243/14 , C07D401/06 , C07D401/14 , C07D403/06 , C07D409/06 , C07D487/04
Abstract: The invention relates to compounds of the formulawhereinR1, R2 are independently from each other aryl or heteroaryl, wherein the heteroaryl group contains one or two heteroatoms, selected from N, O, or S, and wherein the aryl or heteroaryl groups are optionally substituted by 1 to 3 substituents, which are independently from each other halogen, CF3, lower alkoxy or lower alkyl;R3 is hydrogen, lower alkyl, -(CH2)nN(R)2, -(CH2)n-heteroaryl or is a -(CH2)n-non aromatic heterocycle, which heterocycles are optionally substituted by halogen, CF3, lower alkoxy or lower alkyl;R4 is =O, =N(CH2)nCH3 or =N(CH2)nN(R)2;R3 and R4 may be together with the N and C atoms to which they are attached the group -CR5=N-N=; R5 is hydrogen, -(CH2)nN(R)2, -(CH2)n-heteroaryl or is a -(CH2)n-non aromatic heterocycle, which heterocycles are optionally substituted by halogen, CF3, lower alkoxy or lower alkyl;R is hydrogen or lower alkyl;n is 0, 1, 2 or 3;and pharmaceutically acceptable acid addition salts and enantiomeric forms thereof. The compounds are useful in the treatment of diseases, related to the NK-1 receptor.
-
公开(公告)号:DE60031513T2
公开(公告)日:2007-08-30
申请号:DE60031513
申请日:2000-02-15
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: C07C211/44 , C07D213/75 , A61K31/167 , A61K31/44 , A61P25/00 , A61P29/00 , C07C211/54 , C07C233/29 , C07C233/33 , C07C233/44 , C07C317/14 , C07C317/40 , C07C323/41 , C07D213/79 , C07D213/81 , C07D295/12 , C07D295/135 , C07D401/04
Abstract: The present invention is a series of compounds formed from phenyl substituted pyridine or benzene derivatives and their pharmaceutically acceptable salts. These compounds have shown high affinity as antagonists to the NK-1 receptor.
-
公开(公告)号:DE60120419T2
公开(公告)日:2007-06-06
申请号:DE60120419
申请日:2001-07-27
Applicant: HOFFMANN LA ROCHE
Inventor: GODEL THIERRY , HOFFMANN TORSTEN , SCHNIDER PATRICK , STADLER HEINZ
IPC: C07D213/74 , A61K31/44 , A61K31/4427 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/455 , A61K31/496 , A61K31/5377 , A61P1/04 , A61P11/00 , A61P17/02 , A61P25/00 , A61P25/06 , A61P25/28 , A61P25/36 , A61P27/02 , A61P27/16 , A61P29/00 , A61P29/02 , A61P37/00 , A61P37/08 , A61P43/00 , C07D213/75 , C07D213/79 , C07D213/82 , C07D401/04 , C07D401/06 , C07D401/12 , C07D409/04 , C07D413/04 , C07D417/04 , C07D521/00
Abstract: Substituted 4-phenyl-pyridine compounds with activity as antagonists of Neurokinin 1 receptors, methods of making these compounds and preparing.
-
公开(公告)号:DK1296961T3
公开(公告)日:2007-06-04
申请号:DK01960225
申请日:2001-05-18
Applicant: HOFFMANN LA ROCHE
Inventor: GODEL THIERRY , GALLEY GUIDO , GOERGLER ANNICK , HECK REINHARD
IPC: C07D243/08 , A61K31/551 , A61K31/5517 , A61P1/04 , A61P1/08 , A61P9/00 , A61P11/06 , A61P13/10 , A61P17/02 , A61P19/02 , A61P25/00 , A61P25/06 , A61P27/02 , A61P29/00 , A61P37/08 , C07D243/14 , C07D401/06 , C07D401/14 , C07D403/06 , C07D409/06 , C07D487/04
Abstract: The invention relates to compounds of the formulawhereinR1, R2 are independently from each other aryl or heteroaryl, wherein the heteroaryl group contains one or two heteroatoms, selected from N, O, or S, and wherein the aryl or heteroaryl groups are optionally substituted by 1 to 3 substituents, which are independently from each other halogen, CF3, lower alkoxy or lower alkyl;R3 is hydrogen, lower alkyl, -(CH2)nN(R)2, -(CH2)n-heteroaryl or is a -(CH2)n-non aromatic heterocycle, which heterocycles are optionally substituted by halogen, CF3, lower alkoxy or lower alkyl;R4 is =O, =N(CH2)nCH3 or =N(CH2)nN(R)2;R3 and R4 may be together with the N and C atoms to which they are attached the group -CR5=N-N=; R5 is hydrogen, -(CH2)nN(R)2, -(CH2)n-heteroaryl or is a -(CH2)n-non aromatic heterocycle, which heterocycles are optionally substituted by halogen, CF3, lower alkoxy or lower alkyl;R is hydrogen or lower alkyl;n is 0, 1, 2 or 3;and pharmaceutically acceptable acid addition salts and enantiomeric forms thereof. The compounds are useful in the treatment of diseases, related to the NK-1 receptor.
-
公开(公告)号:ES2272264T3
公开(公告)日:2007-05-01
申请号:ES00912462
申请日:2000-02-15
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK
IPC: C07C211/44 , C07D213/75 , A61K31/167 , A61K31/44 , A61P25/00 , A61P29/00 , C07C211/54 , C07C233/29 , C07C233/33 , C07C233/44 , C07C317/14 , C07C317/40 , C07C323/41 , C07D213/79 , C07D213/81 , C07D295/12 , C07D295/135 , C07D401/04
Abstract: Compuestos de la fórmula general en donde R es hidrógeno, inferior C1-C7, alcoxi C1-C7, halóge- no o trifluorometilo; R1 es hidrógeno o halógeno con la condición de que R1 en posición 4 no es bromo o yodo; o R y R1 pueden ser conjuntamente -CH=CH-CH=CH-; R2 es hidrógeno, halógeno, trifluorometilo, alcoxi C1-C7 o ciano, con la condición de que R2 no es hidrógeno, si X es -C(O)O-; R3 es independientemente uno de otro, hidrógeno, al- quilo C1-C7 o forma un grupo cicloalquilo; R4 es hidrógeno, halógeno, alquilo C1-C7, alcoxi C1- C7, -N(R5)2, -N(R5)S(O)2-alquilo C1-C7, -N(R5)C(0)R5 o una amina terciaria cíclica elegida del grupo constituido por pirrol-1-ilo, imidazol-1-ilo, pi- peridin-1-ilo, piperacin-1-ilo, morfolin-4-ilo, tiomorfolin-4-ilo, 1-oxo-tiomorfolin-4-ilo o 1, 1, - dioxo-tiomorfolin-4-ilo, que puede estar no susti- tuido o sustituido por hidroxilo, alquilo C1-C7, -N(R5)CO-alquilo C1-C7, hidroxi-alquilo C1-C7, cia- no, -CHO o por un grupo heterocíclico de 5 o 6 miembros, opcionalmente enlazado vía un grupo al- quileno, elegido del grupo constituido por piridi- nilo, pirimidinilo, oxadiazolilo, triazolilo, te- trazolilo, tiazolilo, tienilo, furilo, piranilo, pirrolilo, imidazolilo, pirazolilo, isotiazolilo, piperacinilo o piperidilo; X es ¿C(O)N(R5)-, -(CH2)mO-, -(CH2)mN(R5)-, -N(R5)C(O)-, -C(O)O-, ó ¿N(R5)(CH2)m-; Y es ¿(CH2)n, -O-, -S-, -SO2-, -C(O)- ó ¿N(R5)-; R5'' es cicloalquilo C3-C6, bencilo o alquilo C1-C7; Z es =N-, -CH= ó ¿C(Cl)=; n es 0-4; y m es 1 ó 2; y sales derivadas de una adición ácida farmacéuticamente aceptables.
-
公开(公告)号:AR045878A2
公开(公告)日:2005-11-16
申请号:ARP040104466
申请日:2004-12-01
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , GODEL THIERRY , RIEMER CLAUS , SLEIGHT ANDREW
IPC: A61K31/63 , A61K31/18 , A61K31/325 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/44 , A61K31/505 , A61P25/00 , C07C311/21 , C07C311/38 , C07C311/44 , C07D209/08 , C07D213/76 , C07D239/48 , C07D239/50 , C07D239/69 , C07D403/04 , C07D209/40 , A61K31/506 , A61P25/18 , A61P25/24 , A61P25/16 , A61P25/28
Abstract: El presente se refiere al uso de compuestos sulfonamidas de fórmula general (1), en donde: Z significa un grupo de fenilo sustituido, piridilo sustituido, primidilo sustituido o indolilo sustituido del grupo de fórmulas (2), R1 significa hidrógeno, amino, alquilamino inferior, dialquilamino inferior, alquilo inferior, halógeno o trifluorometilo; R2 significa hidrógeno o alquilo inferior; R3 significa hidrógeno, amino, alquilamino inferior, dialquilamino inferior, alquilo inferior, CF3, alcoxilo inferior o halógeno; R4 significa amino, alquilamino inferior, dialquilamino inferior, alquilo inferior, alcoxilo inferior o halógeno; R5 significa hidrógeno, alquilamino inferior, dialquilamino inferior, alcoxilo inferior o halógeno; R6 significa alquilo inferior, alquilamino inferior, dialquilamino inferior, alcoxilo inferior, halógeno o CF3; R7 significa amino, alquilamino inferior, dialquilamino inferior, alcoxilo inferior, alquilsulfanilo inferior, mercapto, pirrolidin-1-ilo o azetidin-1-ilo; R8 significa amino, alquilamino inferior, dialquilamino inferior, bencil-amino, alcoxilo inferior, alquilsulfanilo inferior, halógeno, pirrolidin-1ilo o azetidin-1-ilo; R9 y R10 significan cada uno, independientemente, alcoxilo inferior o alquil-amino inferior; R11 significa hidrógeno o halógeno; R12 significa hidrógeno o alquilo inferior; y a significa un doble enlace opcional, con la salvedad de que R7 y R8 no significan simultáneamente metoxilo; así como sus sales farmacéuticamente aceptables, para la producción de medicamentos que contienen los compuestos de fórmula general (1) como sustancias terapéuticamente activas contra trastornos del sistema nervioso central.
-
公开(公告)号:JO2294B1
公开(公告)日:2005-09-12
申请号:JOP20000014
申请日:2000-02-22
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , BRANCA QUIRICO , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: A61K20060101 , A61K31/44 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/444 , A61K31/455 , A61K31/496 , A61P1/00 , A61P9/00 , A61P11/00 , A61P25/00 , A61P25/04 , A61P25/28 , A61P25/30 , A61P27/02 , A61P29/00 , A61P43/00 , C07D20060101 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/63 , C07D213/65 , C07D213/74 , C07D213/75 , C07D213/78 , C07D213/82 , C07D401/04 , C07D401/12 , C07D413/12 , C07D413/14
Abstract: The present invention relates to compounds of the general formula wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R is hydrogen or halogen; or R and R may be together -CH=CH-CH=CH-; R and R are independently from each other hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; or R and R may be together -CH=CH-CH=CH-, optionally substituted by one or two substituents selected from lower alkyl or lower alkoxy; R is hydrogen, lower alkyl or form a cycloalkyl group; R is hydrogen, -N(R )2, -N(R )(CH2)nOH, -N(R )S(O)2-lower alkyl, -N(R )S(O)2-phenyl, -N=CH-N(R )2, -N(R )C(O)R or a cyclic tertiary amine of the group R is, independently from each other, hydrogen, C3-6-cycloalkyl, benzyl or lower alkyl; R is hydrogen, hydroxy, lower alkyl, -(CH2)nCOO-lower alkyl, -N(R )CO-lower alkyl, hydroxy-lower alkyl, cyano, -(CH2)nO(CH2)nOH, -CHO or a 5-or 6 membered heterocyclic group, optionally bonded via an alkylene group, X is -C(O)N(R )-, -(CH2)mO-, -(CH2)mN(R )-, -N(R )C(O)-, or -N(R )(CH2)m-; n is 0-4; and m is 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I show a high affinity to the NK- 1 receptor. They may be used for the treatment of diseases, which relate to NK- 1 receptor antagonists.
-
公开(公告)号:JO2294B
公开(公告)日:2005-09-12
申请号:JO200014
申请日:2000-02-22
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , BRANCA QUIRICO , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
Abstract: The present invention relates to compounds of the general formula wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R is hydrogen or halogen; or R and R may be together -CH=CH-CH=CH-; R and R are independently from each other hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; or R and R may be together -CH=CH-CH=CH-, optionally substituted by one or two substituents selected from lower alkyl or lower alkoxy; R is hydrogen, lower alkyl or form a cycloalkyl group; R is hydrogen, -N(R )2, -N(R )(CH2)nOH, -N(R )S(O)2-lower alkyl, -N(R )S(O)2-phenyl, -N=CH-N(R )2, -N(R )C(O)R or a cyclic tertiary amine of the group R is, independently from each other, hydrogen, C3-6-cycloalkyl, benzyl or lower alkyl; R is hydrogen, hydroxy, lower alkyl, -(CH2)nCOO-lower alkyl, -N(R )CO-lower alkyl, hydroxy-lower alkyl, cyano, -(CH2)nO(CH2)nOH, -CHO or a 5-or 6 membered heterocyclic group, optionally bonded via an alkylene group, X is -C(O)N(R )-, -(CH2)mO-, -(CH2)mN(R )-, -N(R )C(O)-, or -N(R )(CH2)m-; n is 0-4; and m is 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I show a high affinity to the NK- 1 receptor. They may be used for the treatment of diseases, which relate to NK- 1 receptor antagonists.
-
-
-
-
-
-
-
-
-